Drug Trial Radar · NCT03081247
To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Last checked: Nov 20, 2026Latest source record: Aug 2, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Apr 16, 2018
Primary completion
Dec 7, 2018
Study completion Dec 7, 2018
Sponsor
- Lead sponsor
- Pearl Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 16, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 12-week chronic-dosing study to assess the efficacy and safety of BGF MDI compared to BFF MDI in subjects with moderate to very severe COPD.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
BGF 320/14.4/9.6 µg MDIDrug
Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)
BFF 320/9.6 µgDrug
Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Forced expiratory volume area under the curve from 0 to 4 hours (AUC0-4)Time frame: Week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.